Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2 Study of VX-950 in Combination With Peginterferon Alfa-2a (Pegasys®), With Ribavirin (Copegus®) in Subjects With Genotype 1 Hepatitis C Who Have Not Received Prior Treatment
Brief Summary: Study the effectiveness of telaprevir (VX-950) in combination with Pegylated Interferon Alfa 2a (Peg-IFN-alfa-2a) and Ribavirin (RBV) in reducing plasma hepatitis C virus (HCV) ribonucleic acid (RNA) levels


Options:
A: Arm Label: Pegylated-interferon Alfa-2a + Ribavirin (Group A); Type: EXPERIMENTAL; Interventions: Drug: Pegylated-interferon Alfa-2a, Drug: Ribavirin | Arm Label: Pegylated-interferon Alfa-2a + Ribavirin (Group B); Type: EXPERIMENTAL; Interventions: Drug: Pegylated-interferon Alfa-2a, Drug: Ribavirin | Arm Label: Pegylated-interferon Alfa-2a + Ribavirin (Group C); Type: EXPERIMENTAL; Interventions: Drug: Pegylated-interferon Alfa-2a, Drug: Ribavirin | Arm Label: Pegylated-interferon Alfa-2a + Ribavirin (Group D); Type: EXPERIMENTAL; Interventions: Drug: Pegylated-interferon Alfa-2a, Drug: Ribavirin | Arm Label: Pegylated-interferon Alfa-2a + Ribavirin (Group E); Type: EXPERIMENTAL; Interventions: Drug: Pegylated-interferon Alfa-2a, Drug: Ribavirin | Arm Label: Pegylated-interferon Alfa-2a + Ribavirin (Group F); Type: EXPERIMENTAL; Interventions: Drug: Pegylated-interferon Alfa-2a, Drug: Ribavirin | Arm Label: Pegylated-interferon Alfa-2a + Ribavirin (Group NR); Type: EXPERIMENTAL; Interventions: Drug: Pegylated-interferon Alfa-2a, Drug: Ribavirin | Intervention Type: DRUG; Name: Pegylated-interferon Alfa-2a; Assigned to Arm(s): Pegylated-interferon Alfa-2a + Ribavirin (Group A), Pegylated-interferon Alfa-2a + Ribavirin (Group B), Pegylated-interferon Alfa-2a + Ribavirin (Group C), Pegylated-interferon Alfa-2a + Ribavirin (Group D), Pegylated-interferon Alfa-2a + Ribavirin (Group E), Pegylated-interferon Alfa-2a + Ribavirin (Group F), Pegylated-interferon Alfa-2a + Ribavirin (Group NR) | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): Pegylated-interferon Alfa-2a + Ribavirin (Group A), Pegylated-interferon Alfa-2a + Ribavirin (Group B), Pegylated-interferon Alfa-2a + Ribavirin (Group C), Pegylated-interferon Alfa-2a + Ribavirin (Group D), Pegylated-interferon Alfa-2a + Ribavirin (Group E), Pegylated-interferon Alfa-2a + Ribavirin (Group F), Pegylated-interferon Alfa-2a + Ribavirin (Group NR)
B: Arm Label: PegIntron 1.5 ug/kg/wk plus REBETOL; Type: EXPERIMENTAL; Interventions: Biological: PegIntron (peginterferon alfa-2b; SCH 54031), Drug: REBETOL (ribavirin; SCH 18908) | Arm Label: PegIntron 1.0 ug/kg/wk plus REBETOL; Type: EXPERIMENTAL; Interventions: Biological: PegIntron (peginterferon alfa-2b; SCH 54031), Drug: REBETOL (ribavirin; SCH 18908) | Arm Label: PEGASYS 180 ug/wk Plus COPEGUS; Type: ACTIVE_COMPARATOR; Interventions: Biological: PEGASYS (peginterferon alfa-2a), Drug: COPEGUS (ribavirin) | Intervention Type: BIOLOGICAL; Name: PegIntron (peginterferon alfa-2b; SCH 54031); Assigned to Arm(s): PegIntron 1.5 ug/kg/wk plus REBETOL | Intervention Type: BIOLOGICAL; Name: PegIntron (peginterferon alfa-2b; SCH 54031); Assigned to Arm(s): PegIntron 1.0 ug/kg/wk plus REBETOL | Intervention Type: DRUG; Name: REBETOL (ribavirin; SCH 18908); Assigned to Arm(s): PegIntron 1.0 ug/kg/wk plus REBETOL, PegIntron 1.5 ug/kg/wk plus REBETOL | Intervention Type: BIOLOGICAL; Name: PEGASYS (peginterferon alfa-2a); Assigned to Arm(s): PEGASYS 180 ug/wk Plus COPEGUS | Intervention Type: DRUG; Name: COPEGUS (ribavirin); Assigned to Arm(s): PEGASYS 180 ug/wk Plus COPEGUS
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Peginterferon alfa-2a + Ribavirin, Drug: Peginterferon alfa-2a | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Peginterferon alfa-2a + Ribavirin | Intervention Type: DRUG; Name: Peginterferon alfa-2a + Ribavirin; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Peginterferon alfa-2a; Assigned to Arm(s): 1
D: Arm Label: PBO 12 Week+Peg-IFN-alfa-2a, RBV 48 Week; Type: PLACEBO_COMPARATOR; Interventions: Drug: Ribavirin, Drug: Pegylated Interferon Alfa 2a, Other: Placebo | Arm Label: Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 48 Week; Type: EXPERIMENTAL; Interventions: Drug: Telaprevir, Drug: Ribavirin, Drug: Pegylated Interferon Alfa 2a | Arm Label: Telaprevir 12 Week +Peg-IFN-alfa-2a,RBV 24 Week; Type: EXPERIMENTAL; Interventions: Drug: Telaprevir, Drug: Ribavirin, Drug: Pegylated Interferon Alfa 2a | Arm Label: Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 12 Week; Type: EXPERIMENTAL; Interventions: Drug: Telaprevir, Drug: Ribavirin, Drug: Pegylated Interferon Alfa 2a | Intervention Type: DRUG; Name: Telaprevir; Assigned to Arm(s): Telaprevir 12 Week +Peg-IFN-alfa-2a,RBV 24 Week, Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 12 Week, Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 48 Week | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): PBO 12 Week+Peg-IFN-alfa-2a, RBV 48 Week, Telaprevir 12 Week +Peg-IFN-alfa-2a,RBV 24 Week, Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 12 Week, Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 48 Week | Intervention Type: DRUG; Name: Pegylated Interferon Alfa 2a; Assigned to Arm(s): PBO 12 Week+Peg-IFN-alfa-2a, RBV 48 Week, Telaprevir 12 Week +Peg-IFN-alfa-2a,RBV 24 Week, Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 12 Week, Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 48 Week | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): PBO 12 Week+Peg-IFN-alfa-2a, RBV 48 Week

Answer: D